OPR - Delayed Quote • USD GERN May 2024 3.500 call (GERN240517C00003500) Follow 0.4200 +0.1900 (+82.61%) At close: April 26 at 2:44 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for GERN240517C00003500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: GERN Geron to Announce First Quarter 2024 Financial Results on May 2, 2024 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Geron Corporation (NASDAQ:GERN) Is Expected To Breakeven In The Near Future Geron to Participate at Upcoming Investor Conferences in April 5 FDA decisions to watch in the second quarter Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Geron, Madrigal Pharmaceuticals jump on good news from FDA Stocks to Watch Friday: Adobe, Ulta, Fisker Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up Geron Stock Is Soaring After Hours: What's Going On? Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
